Study design and objectives
toxicity, DLTs
DISEASE
FIGHT‐102 was conducted in 2 parts (Figure Primary objectives were to evaluate the safety, tolerability, and dose‐limiting toxicity (DLTs) and to determine the maximum tolerated dose (MTD) and/or the RP2D of pemigatinib. Secondary objectives were to evaluate pemigatinib PK and pharmacodynamics and to assess the preliminary efficacy by ORR in patients with measurable disease. Exploratory objective included DOR.